The CEO of the global organization of health tedros adhanom Ghebreyesus called "scientific breakthrough" results of clinical trials in the UK steroid dexamethasone for the treatment of COVID-19.
As revealed in the Oxford study, anti-inflammatory drug dexamethasone reduces the risk of death in patients with COVID-19, connected to the ventilator, 35% among patients receiving oxygen at 20%. The drug in Britain costs about five pounds (437 rubles - approx. Ed.). The British government on Tuesday has approved dexamethasone for the treatment of COVID-19.
Of ghebreyesus called the test results " great news."
who said that the UK has provided the organization with preliminary outcome data research." We look forward to full data analysis in a few days ", - added in the organization.
in Russia for the treatment COVID-19 first approved the drug "Aviewer" on location " of Favipiravir ". It has proven its effectiveness in clinical trials. In may, the drug was registered by the Ministry of health. As long as you can't buy in a pharmacy, it is available only to hospital patients and used under medical supervision.
The latest information on the situation of COVID-19 in Russia and the world presented on the portal stopmanager. Of the Russian Federation.
<span style="color:darkgray
sections: Politics |